Live Webinar

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Hosted by AJMC and Targeted Oncology

-- Days : -- HRS : -- MIN : -- SEC
Register Now →
Logo Image
|Articles|October 1, 2002

Supplements and Featured Publications

  • Cardiorenal Differences Among NSAIDs and Coxibs: Real-World Experience
  • Volume 8
  • Issue 15 Suppl

Cost of Heart Failure Among Hypertensive Users of Nonspecific NSAIDs and COX-2-Specific Inhibitors

Download PDF: Cost of Heart Failure Among Hypertensive Users of Nonspecific NSAIDs and COX-2-Specific Inhibitors

Articles in this issue

over 23 years ago

Participating Faculty

over 23 years ago

Cardiorenal Differences Among NSAIDs and Coxibs: Real-World Experience

over 23 years ago

Cyclooxygenase-2-Specific Inhibitors and Cardiorenal Function: A Randomized, Controlled Trial of Celecoxib and Rofecoxib in Older Hypertensive Osteoarthritis Patients

over 23 years ago

Prevalence of Cardiovascular Disease Risk Factors Among US Adults With Self-Reported Osteoarthritis: Data from the Third National Health and Nutrition Examination Survey

over 23 years ago

Comparison of the Baseline Cardiovascular Risk Profile Among Hypertensive Patients Prescribed COX-2-Specific Inhibitors or Nonspecific NSAIDs: Data From Real-Life Practice

over 23 years ago

Blood Pressure Destabilization and Related Healthcare Utilization Among Hypertensive Patients Using Nonspecific NSAIDs and COX-2-Specific Inhibitors

over 23 years ago

Differences Between COX-2-Specific Inhibitors: Clinical and Economic Implications

Related Content